Flow cytofluorometric evidence for the differential radioresponsiveness of aneuploid and diploid cervix tumours.
We are presently involved in a prospective study of the relationship between DNA content profiles, and their changes during treatment, determined by flow cytofluorometry, and patient prognosis and response to therapy for cancer of the uterine cervix. To date, 348 patients have been included in the study over a 54-month period. Data on these patients have shown that DNA aneuploid tumours are significantly more radioresponsive than diploid cervix tumours. Analysis of the data on 213 patients with a minimum follow-up time of 15 months has, however, failed to show an overall more favourable prognosis conferred by tumour DNA aneuploidy. Analysis of the relationship between clinical stage and disease state and tumour DNA ploidy, however, suggests that aneuploid tumours metastasize to distant sites at an earlier stage of the disease than diploid tumours and local recurrence rates for diploid tumours, in late stage disease, are double those for aneuploid tumours. Improved staining procedures, and instrument modification, has also shown that cervix tumour heterogeneity is of considerably greater frequency than at first appeared to be the case (approximately 75% of DNA aneuploid tumours show heterogeneity.
D000782:Aneuploidy; D001706:Biopsy; D002470:Cell Survival / Q000528:radiation effects; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics; D004171:Diploidy; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D009364:Neoplasm Recurrence, Local; D011003:Ploidies; D011379:Prognosis; D011446:Prospective Studies; D002583:Uterine Cervical Neoplasms / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy*
D004273:DNA, Neoplasm